Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Huan Zhou, Jing Xie, Xingyu Zhu, Xiaoyi Li, Xiaohui Yu, Yong Zhang, Yue Su, Cuixia He, Minhui Zhu, Xiao li Li, Yuanyuan Liu, Juan Chen, Dongmei Cheng, Mengmeng Chen, Ying Wang, Qin Ge, Ling Fan, Ying Wang, ZhongHuan Shao, Bingyan Liu, Rongfang Shan, Xiangrong Dai, Hongju Wang & Huaxue Wang. (2021) Pharmacokinetic and pharmacodynamic evaluation of the new prolonged-release leuprorelin acetate microspheres for injection compared with Enantone® in healthy Chinese male volunteers. Expert Opinion on Drug Metabolism & Toxicology 17:9, pages 1149-1156.
Read now
Read now
Gincy George, Hans Garmo, Sarah Rudman, Lars Holmberg, David Robinson, Pär Stattin, Jan Adolfsson & Mieke Van Hemelrijck. (2020) Long-term adherence to GnRH agonists in men with prostate cancer. A nation-wide population-based study in prostate cancer data base Sweden. Scandinavian Journal of Urology 54:1, pages 20-26.
Read now
Read now
Jaro Wex, Manpreet Sidhu, Isaac Odeyemi, Ahmed M Abou-Setta, Peny Retsa & Bertrand Tombal. (2013) Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation. ClinicoEconomics and Outcomes Research 5, pages 257-269.
Read now
Read now
Ulf W Tunn, Damian Gruca & Peter Bacher. (2013) Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation. Clinical Interventions in Aging 8, pages 457-464.
Read now
Read now
Articles from other publishers (21)
Vinson Wai-Shun Chan, Aqua Asif, Jasmine Sze-Ern Koe, Alexander Ng, Chi Fai Ng & Jeremy Yuen-Chun Teoh. (2022) Implications and effects of COVID-19 on diagnosis and management of prostate cancer. Current Opinion in Urology 32:3, pages 311-317.
Crossref
Crossref
Ankur Bahl, Senthil Rajappa, Sudhir Rawal, Ganesh Bakshi, Vedang Murthy & Ketaki Patil. (2022) A review of clinical evidence to assess differences in efficacy and safety of luteinizing hormone–releasing hormone (LHRH) agonist (goserelin) and LHRH antagonist (degarelix). Indian Journal of Cancer 59:5, pages 160.
Crossref
Crossref
Meihua Lin, Jian Zhang, Hao Wan, Chengyang Yan & Fan Xia. (2020) Rationally Designed Multivalent Aptamers Targeting Cell Surface for Biomedical Applications. ACS Applied Materials & Interfaces 13:8, pages 9369-9389.
Crossref
Crossref
Chengqian Zhang, Lan Wu, Anjin Tao, Hriday Bera, Xing Tang, Dongmei Cun & Mingshi Yang. (2021) Formulation and in vitro characterization of long-acting PLGA injectable microspheres encapsulating a peptide analog of LHRH. Journal of Materials Science & Technology 63, pages 133-144.
Crossref
Crossref
Yusuf A. Haggag, Ahmed Kh. Abosalha, Murtaza M. Tambuwala, Enass Y. Osman, Sanaa A. El‐Gizawy, Ebtessam A. Essa & Ahmed A. Donia. (2021) Polymeric nanoencapsulation of zaleplon into PLGA nanoparticles for enhanced pharmacokinetics and pharmacological activity. Biopharmaceutics & Drug Disposition 42:1, pages 12-23.
Crossref
Crossref
Mian Fu, Xiaomei Zhuang, Tianhong Zhang, Ying Guan, Qingbin Meng & Yongjun Zhang. (2020) Hydrogen‐Bonded Films for Zero‐Order Release of Leuprolide. Macromolecular Bioscience 20:9.
Crossref
Crossref
Yusuf Haggag, Kyle Matchett, Robert Falconer, Mohammad Isreb, Jason Jones, Ahmed Faheem, Paul McCarron & Mohamed El-Tanani. (2019) Novel Ran-RCC1 Inhibitory Peptide-Loaded Nanoparticles Have Anti-Cancer Efficacy In Vitro and In Vivo. Cancers 11:2, pages 222.
Crossref
Crossref
Philip Cornford, Kieran Jefferson, Owen Cole & John Gilbody. (2018) Effects of Initiating or Switching to a Six-Monthly Triptorelin Formulation on Prostate Cancer Patient–Healthcare Interactions and Hospital Resource Use: a Real-World, Retrospective, Non-Interventional Study. Oncology and Therapy 6:2, pages 173-187.
Crossref
Crossref
Eva M. Bolton & Thomas Lynch. (2018) Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review. BJU International 122:3, pages 371-383.
Crossref
Crossref
Nedal Y. Abu-Thabit & Abdel Salam H. Makhlouf. 2018. Stimuli Responsive Polymeric Nanocarriers for Drug Delivery Applications, Volume 1. Stimuli Responsive Polymeric Nanocarriers for Drug Delivery Applications, Volume 1
3
41
.
Kate McKeage & Katherine A. Lyseng-Williamson. (2017) Triptorelin 3- and 6-month sustained-release formulations in locally advanced or metastatic prostate cancer: a profile of their use in the EU. Drugs & Therapy Perspectives 33:7, pages 321-325.
Crossref
Crossref
Yusuf A. Haggag, Kyle B. Matchett, El-Habib Dakir, Paul Buchanan, Mohammed A. Osman, Sanaa A. Elgizawy, Mohamed El-Tanani, Ahmed M. Faheem & Paul A. McCarron. (2017) Nano-encapsulation of a novel anti-Ran-GTPase peptide for blockade of regulator of chromosome condensation 1 (RCC1) function in MDA-MB-231 breast cancer cells. International Journal of Pharmaceutics 521:1-2, pages 40-53.
Crossref
Crossref
Yuan‐Chi Shen, Chih‐ Hsiung Kang & Po‐Hui Chiang. (2016) Efficacy of switching therapy of luteinizing hormone–releasing hormone analogue for advanced prostate cancer. The Kaohsiung Journal of Medical Sciences 32:11, pages 567-571.
Crossref
Crossref
Axel S. Merseburger & Marie C. Hupe. (2016) An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer. Advances in Therapy 33:7, pages 1072-1093.
Crossref
Crossref
Michele Caruso, Gaetano Castiglione, Rosanna Aiello, Marco Alí, Maurizio Chiarenza, Rosanna Dimarco, Giuseppa Fallica, Maria Grazia Di Leo, Maria Vita Sanó, Eleonora Taibi, Alessandra Zacchia, Eleonora Miano & Francesco Caruso. (2015) 3-month triptorelin in premenopausal patients with hormone receptor-positive early breast cancer: a commentary and a retrospective experience. Future Oncology 11:23, pages 3109-3112.
Crossref
Crossref
Thierry Lebret, Jean-Louis Davin, Christophe Hennequin, Igor Latorzeff, Jean-Pierre Mignard, Jean-Luc Moreau, Dominique Rossi, Alain Ruffion, Marc Zerbib & Stéphane Culine. (2014) Selection criteria for initiation and renewal of luteinizing hormone-releasing hormone agonist therapy in patients with prostate cancer: a French prospective observational study. Therapeutic Advances in Urology 6:6, pages 205-214.
Crossref
Crossref
Nael M. Mostafa, Kristof Chwalisz, Lois Larsen, Cynthia Mattia-Goldberg, Aaron Spitz & Rajendra S. Pradhan. (2014) Evaluation of the pharmacokinetics and pharmacodynamics of two leuprolide acetate 45 mg 6-month depot formulations in patients with prostate cancer. Clinical Pharmacology in Drug Development 3:4, pages 270-275.
Crossref
Crossref
Gábor Mezo. 2013. Amino Acids, Peptides and Proteins. Amino Acids, Peptides and Proteins
203
252
.
Patrizia Limonta & Marilena Manea. (2013) Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies. Cancer Treatment Reviews 39:6, pages 647-663.
Crossref
Crossref
Patrizia Limonta, Marina Montagnani Marelli, Stefania Mai, Marcella Motta, Luciano Martini & Roberta M. Moretti. (2012) GnRH Receptors in Cancer: From Cell Biology to Novel Targeted Therapeutic Strategies. Endocrine Reviews 33:5, pages 784-811.
Crossref
Crossref
Nazila Kamaly, Zeyu Xiao, Pedro M. Valencia, Aleksandar F. Radovic-Moreno & Omid C. Farokhzad. (2012) Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chemical Society Reviews 41:7, pages 2971.
Crossref
Crossref